Maze Therapeutics (MAZE) Competitors

Maze Therapeutics logo
$33.90 -0.43 (-1.25%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$33.44 -0.46 (-1.36%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MAZE vs. CYTK, RYTM, KNSA, IMVT, and ORKA

Should you buy Maze Therapeutics stock or one of its competitors? Maze Therapeutics's main competitors and comparable companies include Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Kiniksa Pharmaceuticals International (KNSA), Immunovant (IMVT), and Oruka Therapeutics (ORKA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Maze Therapeutics compare to Cytokinetics?

Maze Therapeutics (NASDAQ:MAZE) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Maze Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -686.63%. Cytokinetics' return on equity of 0.00% beat Maze Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Maze TherapeuticsN/A -38.39% -32.57%
Cytokinetics -686.63%N/A -48.26%

Maze Therapeutics has higher revenue and earnings than Cytokinetics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maze Therapeutics$167.50M11.07-$131.12M-$2.65N/A
Cytokinetics$88.04M84.13-$784.96M-$6.04N/A

Maze Therapeutics has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

In the previous week, Maze Therapeutics had 7 more articles in the media than Cytokinetics. MarketBeat recorded 20 mentions for Maze Therapeutics and 13 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.60 beat Maze Therapeutics' score of -0.49 indicating that Cytokinetics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maze Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cytokinetics
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive

Maze Therapeutics currently has a consensus target price of $65.50, indicating a potential upside of 93.22%. Cytokinetics has a consensus target price of $106.67, indicating a potential upside of 100.61%. Given Cytokinetics' higher possible upside, analysts plainly believe Cytokinetics is more favorable than Maze Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

Summary

Maze Therapeutics beats Cytokinetics on 9 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Maze Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm Pharmaceuticals$189.76M39.27-$196.54M-$2.90N/A
Maze Therapeutics$167.50M11.07-$131.12M-$2.65N/A

Rhythm Pharmaceuticals presently has a consensus price target of $142.00, suggesting a potential upside of 32.12%. Maze Therapeutics has a consensus price target of $65.50, suggesting a potential upside of 93.22%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Maze Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.77
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08

In the previous week, Maze Therapeutics had 13 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 20 mentions for Maze Therapeutics and 7 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.76 beat Maze Therapeutics' score of -0.49 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rhythm Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Maze Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rhythm Pharmaceuticals has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Maze Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -69.03%. Maze Therapeutics' return on equity of -38.39% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals-69.03% -171.16% -43.00%
Maze Therapeutics N/A -38.39%-32.57%

Summary

Maze Therapeutics beats Rhythm Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Maze Therapeutics compare to Kiniksa Pharmaceuticals International?

Maze Therapeutics (NASDAQ:MAZE) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Kiniksa Pharmaceuticals International has a net margin of 11.58% compared to Maze Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 17.27% beat Maze Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Maze TherapeuticsN/A -38.39% -32.57%
Kiniksa Pharmaceuticals International 11.58%17.27%12.64%

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Maze Therapeutics has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market.

In the previous week, Maze Therapeutics had 10 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 20 mentions for Maze Therapeutics and 10 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.90 beat Maze Therapeutics' score of -0.49 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maze Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kiniksa Pharmaceuticals International
6 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Maze Therapeutics currently has a consensus target price of $65.50, suggesting a potential upside of 93.22%. Kiniksa Pharmaceuticals International has a consensus target price of $100.57, suggesting a potential upside of 6.73%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08
Kiniksa Pharmaceuticals International
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.78

Kiniksa Pharmaceuticals International has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maze Therapeutics$167.50M11.07-$131.12M-$2.65N/A
Kiniksa Pharmaceuticals International$677.56M10.93$59.01M$1.3072.48

Summary

Kiniksa Pharmaceuticals International beats Maze Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Maze Therapeutics compare to Immunovant?

Maze Therapeutics (NASDAQ:MAZE) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Maze Therapeutics' return on equity of -38.39% beat Immunovant's return on equity.

Company Net Margins Return on Equity Return on Assets
Maze TherapeuticsN/A -38.39% -32.57%
Immunovant N/A -63.01%-56.19%

47.1% of Immunovant shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by insiders. Comparatively, 1.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Maze Therapeutics has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

In the previous week, Maze Therapeutics had 8 more articles in the media than Immunovant. MarketBeat recorded 20 mentions for Maze Therapeutics and 12 mentions for Immunovant. Immunovant's average media sentiment score of 0.66 beat Maze Therapeutics' score of -0.49 indicating that Immunovant is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maze Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Immunovant
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Maze Therapeutics currently has a consensus target price of $65.50, suggesting a potential upside of 93.22%. Immunovant has a consensus target price of $44.60, suggesting a potential upside of 34.01%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Immunovant.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08
Immunovant
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.62

Maze Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maze Therapeutics$167.50M11.07-$131.12M-$2.65N/A
ImmunovantN/AN/A-$505.61M-$2.56N/A

Summary

Maze Therapeutics beats Immunovant on 10 of the 13 factors compared between the two stocks.

How does Maze Therapeutics compare to Oruka Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Oruka Therapeutics has lower revenue, but higher earnings than Maze Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maze Therapeutics$167.50M11.07-$131.12M-$2.65N/A
Oruka TherapeuticsN/AN/A-$105.43M-$2.11N/A

Maze Therapeutics presently has a consensus target price of $65.50, indicating a potential upside of 93.22%. Oruka Therapeutics has a consensus target price of $141.80, indicating a potential upside of 42.89%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Maze Therapeutics is more favorable than Oruka Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

Maze Therapeutics has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market.

Oruka Therapeutics' return on equity of -19.34% beat Maze Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Maze TherapeuticsN/A -38.39% -32.57%
Oruka Therapeutics N/A -19.34%-18.74%

56.4% of Oruka Therapeutics shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Oruka Therapeutics had 8 more articles in the media than Maze Therapeutics. MarketBeat recorded 28 mentions for Oruka Therapeutics and 20 mentions for Maze Therapeutics. Oruka Therapeutics' average media sentiment score of -0.01 beat Maze Therapeutics' score of -0.49 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maze Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Oruka Therapeutics
6 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Oruka Therapeutics beats Maze Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Maze Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MAZE vs. The Competition

MetricMaze TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.97B$4.15B$7.84B$12.17B
Dividend YieldN/A3.62%2.46%4.43%
P/E Ratio-12.7927.6734.7128.60
Price / Sales11.0716.368.635.70
Price / CashN/A26.3721.9322.50
Price / Book4.324.074.323.70
Net Income-$131.12M-$22.86M$3.52B$392.17M
7 Day Performance-4.37%-6.13%-4.44%-3.21%
1 Month Performance23.14%-4.90%-3.49%-5.66%
1 Year Performance1.10%-2.99%0.19%-5.97%

Maze Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MAZE
Maze Therapeutics
2.6344 of 5 stars
$33.90
-1.3%
$65.50
+93.2%
+4.2%$1.97B$167.50MN/A141
CYTK
Cytokinetics
3.054 of 5 stars
$56.13
-0.1%
$106.67
+90.0%
-20.0%$7.82B$88.04MN/A673
RYTM
Rhythm Pharmaceuticals
2.7771 of 5 stars
$115.02
+4.7%
$142.00
+23.5%
+8.1%$7.62B$189.76MN/A414
KNSA
Kiniksa Pharmaceuticals International
3.4 of 5 stars
$96.33
+0.1%
$100.57
+4.4%
+133.7%$7.56B$677.56M74.10366
IMVT
Immunovant
2.4369 of 5 stars
$34.18
-2.5%
$44.60
+30.5%
+40.2%$7.25BN/AN/A315

Related Companies and Tools


This page (NASDAQ:MAZE) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners